| Overview |
| bsm-30269A-PE |
| mouse CD105/PE |
| FCM |
| Mouse |
| Specifications |
| Unconjugated |
| Rat |
| Monoclonal |
| 5G8 |
| IgG2a/Kappa |
| n/a |
| Affinity purified by Protein G |
| 0.01M PBS, 0.5%BSA, 0.03% Proclin300 |
| Store at 2-8℃. Protect from light. Avoid freezing. |
| Target |
| 13805 |
| Q63961 |
| END; Endoglin; ENG; FLJ41744; HHT1; ORW; ORW1; Osler Rendu Weber syndrome 1; RP11 228B15.2; CD 105; CD105 antigen; EGLN_HUMAN; EGLN_MOUSE; AI528660; AI662476; S-endoglin; SN6. |
| Enables protein homodimerization activity and transforming growth factor beta binding activity. Involved in several processes, including circulatory system development; positive regulation of cell differentiation; and regulation of gene expression. Acts upstream of or within circulatory system development and positive regulation of angiogenesis. Located in endothelial microparticle. Is expressed in several structures, including brain; cardiovascular system; extraembryonic vascular system; and lung. Used to study arteriovenous malformations of the brain and hereditary hemorrhagic telangiectasia. Human ortholog(s) of this gene implicated in arteriovenous malformation; arteriovenous malformations of the brain; breast cancer; hereditary hemorrhagic telangiectasia; and intracranial aneurysm. Orthologous to human ENG (endoglin). [provided by Alliance of Genome Resources, Apr 2022] |
| Application Dilution |
| FCM |
1:20-100 |
Powered by Bioz